Reporter Account  Create New Account  Login!
Search :
QUICK LINKS : Art & Entertainment Automotive Blogging & Social Media Business Computer Design Education Environment Events / Trade Shows  
Startup Funding Conference
forpressrelease.com
Post Your Story for FREE!
forpressrelease.com
For Press Release Writing
forpressrelease.com
Increase Sales in Just 69 secs!
forpressrelease.com
Platform for Startups
forpressrelease.com
Promote Your Events
forpressrelease.com
 
 
 
Press Release Details    
Add to Favorites  Mail to a Friend Print Page   Share This News Rate
Save This Listing     Stumble It          
130

Advaita Bioinformatics Awarded Competitive Grant from the National Science Foundation

Plymouth, MI (August 13, 2017 )– Advaita Bioinformatics, one of the most innovative companies in the field of Genomics, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant of $225,000 to conduct research and development (R&D) work on a new method of predicting clinically-relevant disease subtypes. Groundbreaking results obtained using real cancer patient data show that Advaita’s proprietary technology is able to distinguish between more and less aggressive types of cancer without any prior knowledge.


Treating specific subtypes of disease can be very effective but depends crucially on the correct disease subtyping. Even for targeted drugs aimed at a very specific type of tumor, some patients respond well whether other patients do not respond at all, or develop resistance over some time.


The fact that a substantial fraction of patients with the same disease respond very differently to the same treatment, is a very important challenge today” says Advaita CEO Sorin Draghici. “We are hoping to take generic treatment and make is personalized and custom for every patient. This avoids unnecessary exposure to ineffective drugs and treatments, shortening the treatment time, decreasing costs and better outcomes for patients, health care professionals and the insurers. These personalized treatments will also benefit the pharmaceutical companies by having a higher chance of approvals for new drugs, especially when our technology is involved in clinical trials.”


“The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts,” said Barry Johnson, Director of the NSF’s Division of Industrial Innovation and Partnerships. “We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology.”


Once a small business is awarded a Phase I SBIR/STTR grant (up to $225,000), it becomes eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales. All proposals submitted to the NSF SBIR/STTR program undergo a rigorous merit-based review process.


To learn more about the NSF SBIR/STTR program, visit: www.nsf.gov/SBIR


About the National Science Foundation's Small Business Programs:


The National Science Foundation (NSF) awards nearly $190 million annually to startups and small businesses through the Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) program, transforming scientific discovery into products and services with commercial and societal impact. The non-dilutive grants support research and development (R&D) across almost all areas of science and technology helping companies de-risk technology for commercial success. The NSF is an independent federal agency with a budget of about $7 billion that supports fundamental research and education across all fields of science and engineering.


To learn more about Advaita Bioinformatics, visit: www.advaitabio.com


About Advaita Bioinformatics:


Advaita Bioinformatics is a leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery and integration of multiple data types. Currently, 9 of the top 10 pharma companies rely on Advaita’s state-of-the-art algorithms to solve complex problems. Advaita provides a suite of advanced analysis software to more that 10,000 registered users worldwide: iPathwayGuide, for functional interpretation of genes and proteins; iVariantGuide, for genetic variant analysis; and iBioGuide, a search engine revealing connections between genes, pathways, SNPs, drugs, and diseases.


###


 

  
 
 

Contact Information

  • Name: Danny Bruce

    Company: advaitabio

    Telphone: -- , -

    Address: 46099 Five Mile Road
    Plymouth, MI 48170
    info@advaitabio.com

    Email: info@advaitabio.com